Rituximab for the maintenance of minimal change nephropathy – A report of two pregnancies
Sign Up to like & getrecommendations! Published in 2020 at "Obstetric Medicine"
DOI: 10.1177/1753495x18813739
Abstract: Rituximab targets the CD20 antigen expressed on B-lymphocytes and is used to treat recurrent minimal change disease, but experience of its use in pregnancy is limited. We describe a 28-year-old Caucasian female, with recurrent nephrotic… read more here.
Keywords: change; maintenance minimal; rituximab maintenance; minimal change ... See more keywords
Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-194832
Abstract: Introduction. Minimal residual disease (MRD) analysis has been largely used in follicular lymphoma (FL) for outcome prediction. However, despite the broad employment of rituximab maintenance for long-term disease control, there are few published data describing… read more here.
Keywords: disease; maintenance; mrd; mrd negativity ... See more keywords
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.19.01073
Abstract: PURPOSE The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final… read more here.
Keywords: maintenance; treatment; follicular lymphoma; rituximab maintenance ... See more keywords
Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
Sign Up to like & getrecommendations! Published in 2017 at "Acta clinica Croatica"
DOI: 10.20471/acc.2017.56.01.20
Abstract: Rituximab is a chimeric monoclonal CD20 antibody used in the treatment of CD20 positive non-Hodgkin lymphomas and has revolutionized treatment approach to these hematologic malignancies in the last decade. The main aim of this review… read more here.
Keywords: rituximab maintenance; maintenance; treatment; follicular lymphoma ... See more keywords